secukinumab (Cosentyx)
secukinumab is an FDA-licensed reference biologic from Novartis Pharmaceuticals Corporation. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2021
Reference approved
Reference product
Cosentyx secukinumab
Novartis Pharmaceuticals Corporation
- Approved
- May 28, 2021
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for secukinumab from the RCSB Protein Data Bank (PDB 9SFX).
Interactive biological assembly from PDB entry 9SFX. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for secukinumab, in chronological order.
Reference approval
Approval date of the reference secukinumab product.
5 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for secukinumab (Cosentyx)?
No 351(k) biosimilars or interchangeable biosimilars referencing secukinumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.